Department of Anesthesiology, Emory University School of Medicine, Atlanta, GA, 30322, USA.
Department of Neurology, Nanjing University School of Medicine, Nanjing, China.
BMC Neurosci. 2018 Apr 12;19(1):20. doi: 10.1186/s12868-018-0418-z.
Stroke is a leading cause of death and disability worldwide, yet there are limited treatments available. Intranasal administration is a novel non-invasive strategy to deliver cell therapy into the brain. Cells delivered via the intranasal route can migrate from the nasal mucosa to the ischemic infarct and show acute neuroprotection as well as functional benefits. However, there is little information about the regenerative effects of this transplantation method in the delayed phase of stroke. We hypothesized that repeated intranasal deliveries of bone marrow stromal cells (BMSCs) would be feasible and could enhance delayed neurovascular repair and functional recovery after ischemic stroke.
Reverse transcription polymerase chain reaction and immunocytochemistry were performed to analyze the expression of regenerative factors including SDF-1α, CXCR4, VEGF and FAK in BMSCs. Ischemic stroke targeting the somatosensory cortex was induced in adult C57BL/6 mice by permanently occluding the right middle cerebral artery and temporarily occluding both common carotid arteries. Hypoxic preconditioned (HP) BMSCs (HP-BMSCs) with increased expression of surviving factors HIF-1α and Bcl-xl (1 × 10 cells/100 μl per mouse) or cell media were administered intranasally at 3, 4, 5, and 6 days after stroke. Mice received daily BrdU (50 mg/kg) injections until sacrifice. BMSCs were prelabeled with Hoechst 33342 and detected within the peri-infarct area 6 and 24 h after transplantation. In immunohistochemical staining, significant increases in NeuN/BrdU and Glut-1/BrdU double positive cells were seen in stroke mice received HP-BMSCs compared to those received regular BMSCs. HP-BMSC transplantation significantly increased local cerebral blood flow and improved performance in the adhesive removal test.
This study suggests that delayed and repeated intranasal deliveries of HP-treated BMSCs is an effective treatment to encourage regeneration after stroke.
中风是全球范围内导致死亡和残疾的主要原因,但可用的治疗方法有限。鼻内给药是一种将细胞疗法递送至大脑的新型非侵入性策略。通过鼻内途径递送的细胞可以从鼻黏膜迁移到缺血性梗死,并显示出急性神经保护和功能益处。然而,关于这种移植方法在中风延迟期的再生作用的信息很少。我们假设,重复的骨髓基质细胞(BMSC)鼻内给药是可行的,并且可以增强缺血性中风后的延迟性神经血管修复和功能恢复。
通过逆转录聚合酶链反应和免疫细胞化学分析,研究了包括 SDF-1α、CXCR4、VEGF 和 FAK 在内的再生因子在 BMSC 中的表达。通过永久性阻断右侧大脑中动脉和暂时阻断双侧颈总动脉,在成年 C57BL/6 小鼠中诱导靶向体感皮层的缺血性中风。在中风后 3、4、5 和 6 天,将缺氧预处理(HP)BMSC(HP-BMSC)(每只小鼠 1×10 个细胞/100μl)或细胞培养基以缺氧预处理的方式鼻内给药。中风后第 6 和 24 小时,将 BrdU(50mg/kg)每日注射至处死。将 BMSC 用 Hoechst 33342 预先标记,并在移植后 6 和 24 小时内在梗死周边区检测到。在免疫组织化学染色中,与接受常规 BMSC 的中风小鼠相比,接受 HP-BMSC 的中风小鼠的 NeuN/BrdU 和 Glut-1/BrdU 双阳性细胞明显增加。HP-BMSC 移植显著增加了局部脑血流量并改善了粘附物去除测试的表现。
这项研究表明,延迟和重复的鼻内给予 HP 处理的 BMSC 是一种有效的治疗方法,可促进中风后的再生。